文献速递间质性肺疾病

特发性肺纤维化患者术前使用吡非尼酮与术后严重呼吸并发症风险降低相关:日本全国数据库倾向性评分匹配分析

Preoperative use of pirfenidone and reduced risk of postoperative severe respiratory complications in patients with idiopathic pulmonary fibrosis: Propensity score-matched analysis using a nationwide database in Japan.
PubMed 文献 · Respirology · 2021-04-18

本研究基于日本全国数据库,纳入2010年7月至2018年3月接受全身麻醉手术的特发性肺纤维化(IPF)患者631例,其中19%术前接受吡非尼酮治疗。经1:4倾向性评分匹配后,术前吡非尼酮治疗与术后严重呼吸并发症发生风险显著降低相关(OR 0.24,95%CI 0.07-0.76,p=0.015)。

要点

  • 术前吡非尼酮治疗与IPF患者术后严重呼吸并发症风险降低独立相关。
  • 匹配后分析显示OR为0.24(95%CI 0.07-0.76,p=0.015)。
  • 吡非尼酮可能有助于预防全麻手术IPF患者的术后严重呼吸并发症。

核心结论

  • 在日本全国队列中,IPF患者术前接受吡非尼酮治疗与术后严重呼吸并发症风险显著降低相关。

研究设计与样本

  • 基于日本诊断程序组合(DPC)数据库的回顾性队列研究,识别2010年7月至2018年3月接受全身麻醉手术的IPF患者。
  • 共纳入631例患者,其中19%术前接受吡非尼酮治疗;采用1:4倾向性评分匹配,匹配后吡非尼酮组121例,对照组510例。

主要发现

  • 匹配前对照组30天死亡率为3.1%,吡非尼酮组为1.7%。
  • 倾向性评分匹配后,术前吡非尼酮治疗与术后严重呼吸并发症比例降低显著相关(OR 0.24;95%CI 0.07-0.76;p=0.015)。

关键数值与推荐

  • 术后严重呼吸并发症定义为术后30天内接受气管插管机械通气和/或静脉输注大剂量糖皮质激素及院内死亡。

临床怎么用

  • 对于计划接受全身麻醉手术的IPF患者,术前考虑使用吡非尼酮可能有助于降低术后严重呼吸并发症风险。

局限性

  • 本研究为回顾性数据库分析,可能存在未测量的混杂因素。

以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。

原文

BACKGROUND AND OBJECTIVE: Patients with idiopathic pulmonary fibrosis (IPF) often develop postoperative severe respiratory complications such as acute exacerbation. Pirfenidone, an oral anti-fibrotic drug, may reduce the incidence of such complications. However, the preventive effect of pirfenidone on postoperative severe respiratory complications remains unclear. METHODS: We identified patients with IPF who underwent surgery with general anaesthesia from July 2010 to March 2018 using the Diagnosis Procedure Combination database. We compared the occurrence of postoperative severe respiratory complications (receiving mechanical ventilation under endotracheal intubation and/or intravenous infusion of a high-dose corticosteroid and in-hospital death within 30 days after surgery) between patients who did and did not receive preoperative treatment with pirfenidone. Pearson's chi-square test and logistic regression analysis fitted with a generalized estimating equation were conducted in 1:4 propensity score-matched patients. RESULTS: Among 631 patients identified, 19% were treated with pirfenidone before surgery. The 30-day mortality rate was 3.1% and 1.7% in the control patients (n = 510) and pirfenidone-treated patients (n = 121), respectively. In the propensity score-matched population, preoperative treatment with pirfenidone was significantly associated with a lower proportion of postoperative severe respiratory complications (OR: 0.24; 95% CI: 0.07-0.76; p = 0.015). CONCLUSION: In this Japanese nationwide cohort, preoperative treatment with pirfenidone was significantly associated with a lower risk of postoperative severe respiratory complications in patients with IPF. Preoperative pirfenidone may thus be useful in preventing postoperative severe respiratory complications in patients with IPF who are planning to undergo surgery with general anaesthesia.

来源:Respirology,查看原文。版权归原作者所有。

引用

  1. Urushiyama H, Jo T, Hasegawa W, et al. Preoperative use of pirfenidone and reduced risk of postoperative severe respiratory complications in patients with idiopathic pulmonary fibrosis: Propensity score-matched analysis using a nationwide database in Japan. Respirology. 2021. PMID: 33870611. doi:10.1111/resp.14044

供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。